Advertisement
Singapore markets closed

  • Straits Times Index

    3,348.87
    +12.28 (+0.37%)
     

  • S&P 500

    5,288.40
    +10.89 (+0.21%)
     

  • Dow

    38,616.26
    -70.06 (-0.18%)
     

  • Nasdaq

    16,841.52
    +106.50 (+0.64%)
     

  • Bitcoin USD

    69,944.96
    +1,821.63 (+2.67%)
     

  • CMC Crypto 200

    1,503.11
    +35.17 (+2.40%)
     

  • FTSE 100

    8,310.48
    +35.10 (+0.42%)
     

  • Gold

    2,352.10
    +6.30 (+0.27%)
     

  • Crude Oil

    75.54
    -1.45 (-1.88%)
     

  • 10-Yr Bond

    4.4570
    -0.0570 (-1.26%)
     

  • Nikkei

    38,923.03
    +435.13 (+1.13%)
     

  • Hang Seng

    18,403.04
    +323.43 (+1.79%)
     

  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     

  • Jakarta Composite Index

    7,036.19
    +65.46 (+0.94%)
     

  • PSE Index

    6,470.74
    +37.64 (+0.59%)
     

Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

Renalytix plc
·2-min read
Renalytix plc
Renalytix plc

LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.

Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link: https://edge.media-server.com/mmc/p/k57ufszy

ADVERTISEMENT

For further information, please contact:

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

 

 

CapComm Partners

 

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

 

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.